imatinib mesylate

Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively).

Norimatinib mesylate, also known as N-Desmethyl imatinib mesylate, is a metabolite derived from Imatinib, which acts as a potent multi-target inhibitor of v-Abl, c-Kit, and PDGFR.

AP23464 represents a highly specialized ATP-based small molecule tyrosine kinase inhibitor specifically engineered to target the catalytic domain of Abl and Src kinases along with the Kit receptor with exceptional inhibitory potency and selectivity, effectively facilitating the measurable blockade of phosphorylation-mediated signaling across various preclinical experimental models to evaluate the suppression of oncogenic driver activities during strictly monitored laboratory observation periods and biochemical investigations to ensure high experimental sensitivity.